Advertisement

TheBodyPRO.com Covers CROI 2016

News

New HIV Treatments Discussed at CROI 2016

March 1, 2016

While new HIV prevention methods got the most attention at this year’s Conference on Retroviruses and Opportunistic Infections (CROI), which took place last week in Boston, researchers also presented studies of new drugs for HIV therapy. Two of these are being tested for both treatment and pre-exposure prophylaxis (PrEP).


Long-Acting Cabotegravir and Rilpivirine

The most exciting prospect are long-acting injectable antiretrovirals that can be taken once monthly or even quarterly. Long-acting medications could offer an attractive option for people with HIV facing a lifetime of treatment.

David Margolis, M.D. (Credit: Liz Highleyman)

David Margolis, M.D. (Credit: Liz Highleyman)

David Margolis, M.D., from ViiV Healthcare presented findings from the LATTE 2 trial, which tested a pair of long-acting injectables—cabotegravir and rilpivarine—for HIV maintenance therapy.

In preparation for testing the long-acting injectables, the original LATTE study previously showed that oral cabotegravir plus oral rilpivirine (Edurant) was safe and maintained viral suppression in people who achieved undetectable viral load using a standard three-drug regimen. Demonstrating the safety and effectiveness of an oral version of this regimen was important because the injectable versions cannot be removed from the body after administration.

The 309 previously untreated participants in LATTE 2 first started a three-drug regimen containing oral cabotegravir plus abacavir/lamivudine (the drugs in Epzicom). The 286 people who achieved viral suppression then went on to the maintenance phase, where they were randomly assigned to receive intramuscular injections of cabotegravir and rilpivirine every 4 weeks (Q4W), every 8 weeks (Q8W), or to stay on the same oral regimen.

During the maintenance phase, 94% of participants who received the injections every 4 weeks and 95% of those treated every 8 weeks maintained undetectable viral load at 32 weeks, as did 91% of those who stayed on the oral regimen.

Injectable cabotegravir and rilpivirine were generally safe and well tolerated with few serious adverse events. However, more than 90% of participants who received the shots reported injection site reactions such as pain or swelling. The regimen requires two separate 2-3 ml injections of cabotegravir and rilpivirine in the gluteal muscle (the butt), which is quite a large volume. Most of these reactions were mild or moderate and usually resolved in about three days. Only two people withdrew from the study for this reason.

Despite the injection problems, study participants reported a high level of satisfaction with their treatment. More than 90% of people taking the long-acting injectable said that they were satisfied, compared to about 70% of those on the oral regimen.

This excerpt was cross-posted with the permission of BETAblog.org. Read the full article.




This article was provided by BETA. It is a part of the publication The 23rd Conference on Retroviruses and Opportunistic Infections. Visit their website at www.betablog.org.
 


No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

Advertisement

The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.